Artificial Lung Market

The Global Artificial Lung Market is estimated to be valued at USD 2.10 Bn in 2025 and is expected to reach USD 4.12 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032. The global artificial lung market represents a critical segment within the broader medical device industry, focusing on advanced life-support technologies designed to temporarily or permanently replace natural lung function in patients with severe respiratory conditions.

Artificial lungs, also known as extracorporeal membrane oxygenation (ECMO) systems or mechanical lung support devices, serve as vital therapeutic solutions for patients suffering from acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), pulmonary embolism, and other life-threatening respiratory failures. These sophisticated biomedical devices function by oxygenating blood and removing carbon dioxide outside the body, effectively performing the gas exchange function typically handled by healthy lungs.

The market encompasses various technological approaches, including membrane oxygenators, artificial lung implants, and wearable artificial lung systems, each designed to address specific patient needs and clinical scenarios. With the increasing prevalence of respiratory diseases globally, aging populations, and the recent impact of respiratory pandemics, the artificial lung market has gained significant attention from healthcare providers, medical device manufacturers, and investors seeking innovative solutions to address critical care challenges and improve patient outcomes in intensive care settings.

Market Dynamics

The global artificial lung market is primarily driven by the escalating prevalence of respiratory diseases worldwide, including chronic obstructive pulmonary disease, acute respiratory distress syndrome, and pulmonary fibrosis, which collectively affect millions of patients globally and create substantial demand for advanced respiratory support technologies. The aging global population significantly contributes to market growth, as elderly individuals are more susceptible to respiratory complications and require intensive care interventions, while technological advancements in biocompatible materials, miniaturization, and improved gas exchange efficiency have enhanced the performance and safety profiles of artificial lung systems.

The COVID-19 pandemic has particularly accelerated market expansion by highlighting the critical need for respiratory support devices and increasing healthcare infrastructure investments globally. However, market growth faces considerable restraints, including the extremely high costs associated with artificial lung devices and their maintenance, complex regulatory approval processes that can delay product launches, and the significant risk of complications such as bleeding, infection, and thrombosis associated with these invasive procedures. The shortage of skilled healthcare professionals trained in operating sophisticated artificial lung systems, coupled with limited availability of these devices in developing regions, further constrains market penetration. Nevertheless, substantial opportunities exist through ongoing research and development in bioengineering, particularly in developing implantable artificial lungs and wearable devices that could revolutionize patient care.

The integration of artificial intelligence and machine learning technologies for predictive monitoring and automated adjustments presents promising avenues for market expansion, while increasing healthcare expenditure in emerging markets and growing awareness about advanced respiratory care solutions create new growth opportunities. Strategic partnerships between medical device manufacturers and healthcare institutions, along with government initiatives supporting critical care infrastructure development, are expected to drive sustained market growth and innovation in the artificial lung sector.

Key Features of the Study

• This report provides in-depth analysis of the global artificial lung market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global artificial lung market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Medtronic plc, Getinge AB, LivaNova PLC, Terumo Corporation, Fresenius Medical Care AG & Co. KGaA, ALung Technologies, Inc., Breethe, Inc., Miromatrix Medical Inc., Abiomed, Inc., Cyanagen Srl, Nipro Corporation, and Hemovent GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global artificial lung market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global artificial lung market

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
• Extracorporeal Membrane Oxygenation (ECMO) Systems
• Veno-Arterial (VA) ECMO
• Veno-Venous (VV) ECMO
• Paracorporeal Artificial Lungs
• Pumpless Paracorporeal Devices
• Pump-Assisted Paracorporeal Devices
• Implantable Artificial Lungs
• Intrathoracic Devices
• Vascular Graft-Integrated Devices
• Others (Oxygenators)
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
• Perfusion Systems
• Membrane Oxygenation Technology
• Microfluidic Oxygenators
• Biohybrid Systems
• Pumpless Gas Exchange Systems
• Others (3D-Printed Artificial Lung Constructs, etc.)
• Portability Insights (Revenue, USD Bn, 2020 - 2032)
• Stationary Systems
• Portable Systems
• Wearable Systems
• Application Insights (Revenue, USD Bn, 2020 - 2032)
• Lung Transplant Support (Bridge-to-Transplant)
• Acute Respiratory Distress Syndrome (ARDS)
• Chronic Respiratory Conditions (COPD, Pulmonary Hypertension, Cystic Fibrosis)
• Others (Coronary Artery Bypass Grafting, etc.)
• Patient Type Insights (Revenue, USD Bn, 2020 - 2032)
• Neonates
• Pediatric
• Adult
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals
• Transplant Centers
• Ambulatory Surgical Centers
• Emergency and Trauma Centers
• Home Care Settings (for wearable devices)
• Others (Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Medtronic plc
• Getinge AB
• LivaNova PLC
• Terumo Corporation
• Fresenius Medical Care AG & Co. KGaA
• ALung Technologies, Inc.
• Breethe, Inc.
• Miromatrix Medical Inc.
• Abiomed, Inc.
• Cyanagen Srl
• Nipro Corporation
• Hemovent GmbH

Show more